Audit: QRS - Mastic Gum for Health & Longevity

Audit conducted on 27/08/2026 09:20 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	82
Failed	0
N/A	11
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Protocol, time-to-effect, benefits, risks, gates, markers and cadence all trace to ER lines 331–357, 381–405, 438, 466–489, 509–513.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	No cautious ER phrasing is converted to a firmer form; “with no head-to-head trial” and “diagnosed bowel disease only” are carried over.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	“Pregnancy or breastfeeding” stays in the Contraindications gate, not the Key Interactions gate; no directional shift found.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Gates draw only on ER Key Interactions & Contraindications; Risk-Modifying Factors (ER 310–326) are not surfaced as side effects.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	Only “Mastisol” appears as a brand name; present in ER line 353 for the same fact. No PMIDs or NCT IDs in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	Trial references (“both lipid trials”, “the gastroparesis trial”, “the mastic beverage trial”) are the ER’s own wording.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Measured, sceptical register matches ER Conclusion and Expected Benefits.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Tiered benefits and concrete targets present the decision without hedging or exhortation.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Doses are stated as trial protocols, not instructions.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperative clinical directions outside the fixed template disclaimer.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No “recommend”, “advise”, or “should” in the QRS body.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the document.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms retained are load-bearing thresholds and biomarker names taken from the ER.
2.8	Information is presented in a concise and very compact manner	🟢	Gate and tier items are stripped to the key fact; no trailing rationale.
2.9	It DOES NOT address the reader directly	🟢	Confirmed by full-text scan for “you”/”your”.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Functional monitoring ranges and form-specific dosing assume a proactive, self-monitoring reader.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Split three-times-daily dosing and a ten-marker monitoring panel are presented without softening.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No simplification to a single consumer takeaway.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-A-Glance flags that the lipid effect applies “where levels are raised”, matching the ER’s benefit-modifying framing.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“anti-aging” does not occur; title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Body uses formal terms throughout; the plain-language wording in At-A-Glance is required by item 7.4 and is the ER Conclusion’s own phrasing.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	Structural diff against the template shows no change to any fixed heading, gate head, tier label or column header.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 template variable names present; marker_#_* and qualitative_item_# correctly instantiated as marker_1–10 and qualitative_item_1–7.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Diff confirms only variable spans and frontmatter differ; CSS, footer disclaimer and website="..." spans are untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No ER section mapped to a QRS field is empty; the Risks-High subsection is governed by item 13.5.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Standard oral dose”, “Dyspepsia protocol”, “Essential-oil alternative” are verbatim ER bold labels (ER 381, 383, 387).
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Time-to-effect labels are drawn from the ER Time to effect bullet wording (ER 438).
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Zero emoji characters in the file; the ER’s “⚠️ Conflicted” markers are correctly not carried over.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed to the minimum permitted by items 9.2, 14.2 and 15.2, which mandate full coverage of the ER’s ten interactions, ten biomarkers and seven qualitative markers.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after the doctype.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening “—” line 3, closing “—” line 13.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no duplicate on the page.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, correctly, because it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: mastic_gum_2026-0827-0656_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: 26.7.02, matching QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: 2026-0827-0903.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	Single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” carries no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the actual filename.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Verified across all nine keys.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Mastic Gum for Health & Longevity - Quick Reference Sheet”.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Mastic Gum for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: 08/27/2026, matching qrs_creation_date 2026-0827-0903.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header holds only title and the template subline; the ER’s “Also known as” line is not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses ER 509–513 into firm findings, weaker signals and drawbacks.
7.2	[at_a_glance] is no longer than 60 words	🟢	Exactly 60 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause maps to a distinct sentence in ER Conclusion (509, 511).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	“so-called bad cholesterol”, “blood sugar”, “belly-fat” replace LDL, glycaemia and visceral fat.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial name, year or sample size.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numbers of any kind.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Sourced from “Populations who should avoid Mastic Gum” (ER 351–357).
8.2	[stop_items] represent the Contraindications from the ER	🟢	All five ER bullets represented, one-to-one.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Five <li> elements, lines 569–576.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	“on the grounds of untested safety rather than known harm” and “in whom no trial has enrolled participants” correctly stripped; no dash-trailing clauses.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“Child-Pugh Class B or C”, “eGFR below 30 mL/min/1.73 m²”, “after 60” and “(chewed resin only)” all preserved.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in the contraindication bullets.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	N/A	The section is not empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Sourced from ER 331–349.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All ten ER interaction bullets present; no overlap with the Contraindications gate.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Ten <li> elements, lines 584–593.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Caution/Monitor labels, mechanisms and all “Mitigation:” clauses stripped; no dash-trailing content.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every bullet keeps a trimmed example-drug parenthetical; none dropped entirely.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in the interaction bullets.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	N/A	The section is not empty.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	Sourced from ER Therapeutic Protocol (381–405).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Reference dose, the dyspepsia regimen and the essential-oil alternative are the three regimens tied to the ER’s High-tier benefits.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies more than three; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine fields populated from ER 381, 383 and 387.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Cholesterol, dyspepsia symptoms and bowel/liver endpoints, the three timeframes named in ER 438.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Both High-tier benefits precede the Medium/Low-tier bowel and liver endpoints.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three; all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine fields populated from ER 438 and 466.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	Sourced from ER 151–241.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans populated.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each tier is a semicolon-separated list of the ER’s benefit headings with no magnitudes or trial detail.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheticals remain.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers carry items in the ER.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	Sourced from ER 265–305.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present; high correctly hidden.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Tiers reproduce the ER risk headings only; the 72% patch-test figure and Conflicted markers are excluded.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheticals remain.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER records no High risk; line 605 sets style="display: none" on [risks_high] with no empty-state text rendered.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Sourced from ER Monitoring Protocol & Defining Success (466–479).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All ten ER table rows present, with targets reproduced exactly.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Lines 779–782 carry the eight-week / six-month / annual lipid and glucose schedule plus twice-weekly home blood pressure, from ER 466.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Sourced from the qualitative-marker list at ER 483–489.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All seven ER bullets present as qualitative_item_1 through qualitative_item_7.

Issues 27/08/2026 09:20

Pass rate 100.00%. No issues found.

Issues 27/08/2026 09:06

1. 4.5 — QRS overruns one A4 page: The sheet’s densest fields were not condensed to their per-section budgets — ten Key Interactions carry full three-to-four-drug parentheticals (lines 588–607), all ten Monitoring “Why” cells wrap to two rendered lines (lines 653–795), and benefits_medium packs six full ER headings (lines 539–546) — pushing the rendered sheet past a single A4 page.

Fixes 27/08/2026 09:06

1. 4.5 — Key Interactions drug lists trimmed: Shortened every example drug parenthetical to the two or three leading examples (e.g. antidiabetics from “metformin, glipizide, glimepiride, insulin” to “metformin, insulin”), per item 9.5’s allowance to trim for the one-page budget while never dropping the list entirely. All ten interactions remain.
2. 4.5 — Monitoring “Why” cells condensed: Rewrote all ten rationale cells to single-line phrases (e.g. marker_10_why from “The endpoint of the hypertension trial and the marker most likely to overshoot on combined therapy” to “The hypertension trial’s endpoint; most likely to overshoot”), and tightened monitoring_cadence. All ten markers and their targets are unchanged.
3. 4.5 — Benefits and Contraindications tightened: Merged the repeated “reduction in / improvement in” stems in benefits_medium, trimmed benefits_low (“liver fat and enzymes”, “hard chewing”), and shortened two contraindication qualifiers to “(chewed resin only)” and “new dyspepsia after 60”. No benefit or contraindication was dropped.
4. 4.5 — Qualitative items shortened: Reduced the trailing clauses on the jaw-symptom and wellbeing items (e.g. “which improved on both quality-of-life scales in the essential-oil trial” to “improved on both quality-of-life scales”) and trimmed the daily-symptom item. All seven items remain.